News | April 08, 2025
NATCO Pharma updates on legal proceedings on Risdiplam launch in India
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Subscribe To Our Newsletter & Stay Updated
